The investigational product is 95% pure montbretin A (MbA), a glycosylated acyl-flavonol isolated from the corms (bulbs) of the Crocosmia plant through hot water extraction. It is a potent and specific inhibitor of human pancreatic amylase (HPA). MbA holds promise as a treatment for diabetes and obesity by limiting post-prandial glucose following a meal.~The purpose of this trial is to establish that montbretin A is safe to consume and will show a better tolerability profile, with respect to gastrointestinal disturbances. This will be demonstrated by charting the amount and rate of colonic fermentation following a meal eaten with a dose of montbretin A. This is a Phase I study.
The goal of this clinical trial is to establish that montbretin A is safe to consume and well tolerated for individuals with Type 2 Diabetes.~The trial aims to determine a safe dosage range and identify any potential side effects.~Participants will participate in the study over a period of time, during which the study participant will be ingesting montbretin A on a pre-determined schedule with continuous monitoring.